Hub : Traits :

Mood swings

547 significantly associated models · 76 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	205517299	205921859	1	1	1.9e-08	1.5e-06	7.8e-01	100	SLC41A1
2	3	48381826	51043528	14	2	1.4e-12	1.5e-10	1.2e-01	94	GPX1 RBM6
3	5	147516165	148067337	1	1	1.1e-07	5.4e-09	1.5e-02	83	FBXO38
4	7	11553163	12967449	1	1	1.5e-09	3.3e-09	1.2e-01	93	TMEM106B
5	8	8092025	11860845	9	1	6.8e-10	8.5e-10	1.4e-01	94	AF131215.2
6	8	140969818	142706843	1	1	4.4e-10	7.8e-09	7.1e-01	100	PTK2
7	9	119768572	121177842	1	1	8.1e-09	1.2e-08	1.0e+00	100	TLR4
8	11	46578400	48559571	8	1	2.8e-12	1.1e-11	2.0e-01	96	MADD
9	11	112542418	113969669	4	3	1.8e-09	4.0e-13	7.3e-04	78	ANKK1 DRD2 RP11-159N11.4
10	12	121453962	122915054	1	1	1.3e-07	5.4e-09	1.2e-02	81	TMEM120B
11	14	74531485	76089054	3	1	1.5e-08	1.6e-09	3.5e-02	88	DLST
12	16	86667409	89428967	3	2	1.0e-08	1.4e-08	1.0e+00	100	FBXO31 MVD
13	17	42607368	45796313	20	1	2.6e-17	4.2e-15	5.7e-01	100	WNT3
14	18	49172179	51753106	1	1	1.5e-07	8.7e-12	3.1e-06	53	DCC
15	18	52209411	54028036	1	1	1.0e-13	1.4e-13	8.0e-02	94	TCF4
16	22	40472399	42614362	7	1	3.0e-11	2.5e-12	2.0e-02	89	SLC25A17

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Neuroticism score	18.40	19	13	28.9	0.98	1.2e-12	AF131215.2 ANKK1 DCC DLST DRD2 FBXO31 FBXO38 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 SLC25A17 SLC41A1 TCF4 TLR4 TMEM106B WNT3
Depressed Affect (Nagel 2018)	16.81	17	13	28.9	0.99	8.2e-14	ANKK1 DCC DLST DRD2 FBXO31 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 SLC41A1 TCF4 TLR4 TMEM106B TMEM120B WNT3
Neuroticism	16.53	17	14	31.1	0.98	1.7e-11	ANKK1 DLST DRD2 FBXO31 FBXO38 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 SLC25A17 SLC41A1 TCF4 TLR4 TMEM106B WNT3
Neuroticism (Nagel 2018)	16.46	17	12	26.7	0.97	6.2e-11	ANKK1 DCC DLST DRD2 FBXO31 FBXO38 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 SLC25A17 TCF4 TLR4 TMEM106B WNT3
Miserableness	13.84	10	8	17.8	0.98	6.8e-07	AF131215.2 ANKK1 DRD2 GPX1 MADD RBM6 RP11-159N11.4 TCF4 TMEM106B WNT3
Fed-up feelings	11.14	12	7	15.6	0.99	5.7e-09	AF131215.2 DCC DLST DRD2 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 TLR4 WNT3
Irritability	10.31	10	4	8.9	0.97	2.2e-06	AF131215.2 ANKK1 DRD2 GPX1 MVD SLC25A17 TCF4 TLR4 TMEM106B WNT3
Worry (Nagel 2018)	10.17	10	6	13.3	1.00	1.3e-09	ANKK1 DLST DRD2 FBXO31 FBXO38 MADD RP11-159N11.4 SLC25A17 TMEM106B WNT3
Neuroticism (2016)	9.90	8	2	4.4	0.98	1.9e-05	AF131215.2 DRD2 GPX1 MADD SLC25A17 TCF4 TLR4 WNT3
Guilty feelings	9.60	7	4	8.9	0.98	1.4e-04	AF131215.2 ANKK1 DLST DRD2 MADD RP11-159N11.4 WNT3
Worrier / anxious feelings	9.43	6	5	11.1	0.95	3.3e-03	AF131215.2 DLST SLC25A17 TCF4 TLR4 WNT3
Sensitivity / hurt feelings	8.73	7	4	8.9	0.99	3.4e-05	AF131215.2 ANKK1 DRD2 FBXO31 PTK2 RP11-159N11.4 WNT3
Frequency of depressed mood in last 2 weeks	8.43	6	0	0.0	0.99	7.0e-05	AF131215.2 ANKK1 DRD2 MADD TMEM106B WNT3
Suffer from 'nerves'	8.30	6	3	6.7	0.97	1.2e-03	AF131215.2 ANKK1 DLST DRD2 MADD WNT3
Nervous feelings	8.16	7	3	6.7	0.98	1.0e-04	AF131215.2 ANKK1 DLST FBXO38 MADD SLC25A17 WNT3
Frequency of tenseness / restlessness in last 2 weeks	8.01	7	1	2.2	1.00	2.4e-06	ANKK1 DRD2 GPX1 MADD RBM6 TMEM106B WNT3
Tense / 'highly strung'	7.76	6	2	4.4	0.99	1.8e-04	AF131215.2 ANKK1 DRD2 RP11-159N11.4 SLC25A17 TMEM106B
Depression (Nagel 2018)	7.39	6	1	2.2	0.98	3.9e-04	ANKK1 DCC MADD RP11-159N11.4 TMEM106B WNT3
Seen doctor (GP) for nerves, anxiety, tension or depression	7.34	5	3	6.7	0.98	3.6e-03	ANKK1 DRD2 GPX1 TCF4 TMEM106B
Loneliness, isolation	7.25	5	2	4.4	0.98	2.9e-03	GPX1 MADD RP11-159N11.4 TMEM106B WNT3
Frequency of unenthusiasm / disinterest in last 2 weeks	7.20	5	0	0.0	0.97	5.7e-03	ANKK1 DCC DRD2 GPX1 RP11-159N11.4
Overall health rating	6.61	7	3	6.7	0.98	1.6e-04	ANKK1 FBXO38 GPX1 PTK2 RBM6 RP11-159N11.4 TMEM120B
Worry too long after embarrassment	6.10	5	2	4.4	0.97	6.6e-03	AF131215.2 ANKK1 DRD2 RP11-159N11.4 WNT3
Frequency of tiredness / lethargy in last 2 weeks	6.00	4	0	0.0	0.86	1.4e-01	DCC GPX1 PTK2 TMEM106B
Hair/balding pattern: Pattern 4	5.96	1	1	2.2	0.00	1.0e+00	WNT3
Taking other prescription medications	5.69	4	1	2.2	0.99	6.4e-03	DLST GPX1 RBM6 TMEM120B
Lung FEV1/FVC ratio	5.37	4	2	4.4	-0.80	2.0e-01	DLST FBXO38 PTK2 SLC41A1
Qualifications: College or University degree	5.33	4	3	6.7	-0.96	3.7e-02	FBXO31 GPX1 RBM6 WNT3
Forced expiratory volume in 1-second (FEV1), Best measure	5.31	4	3	6.7	-0.94	6.4e-02	FBXO38 GPX1 MVD WNT3
Seen a psychiatrist for nerves, anxiety, tension or depression	5.21	1	0	0.0	0.00	1.0e+00	TMEM106B
Major Depression (MDD)	5.18	3	0	0.0	0.00	1.0e+00	GPX1 TCF4 TMEM106B
Forced expiratory volume in 1-second (FEV1)	5.12	3	3	6.7	0.00	1.0e+00	FBXO38 GPX1 WNT3
Hair/balding pattern: Pattern 3	5.01	1	1	2.2	0.00	1.0e+00	WNT3
Alcohol intake frequency.	4.89	7	3	6.7	0.29	5.3e-01	DCC DRD2 MADD RBM6 RP11-159N11.4 TCF4 WNT3
Number of treatments/medications taken	4.67	3	2	4.4	0.00	1.0e+00	DLST GPX1 RBM6
Body mass index (BMI)	4.65	5	4	8.9	0.30	6.2e-01	AF131215.2 GPX1 MADD RBM6 TMEM120B
Age at last live birth	4.56	2	2	4.4	0.00	1.0e+00	GPX1 RBM6
Leg fat mass (left)	4.55	7	5	11.1	0.46	2.9e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Peak expiratory flow (PEF)	4.50	4	3	6.7	-0.69	3.1e-01	AF131215.2 FBXO38 SLC41A1 WNT3
Financial situation satisfaction	4.48	1	1	2.2	0.00	1.0e+00	GPX1
Qualifications: A levels/AS levels or equivalent	4.43	3	2	4.4	0.00	1.0e+00	GPX1 RBM6 TMEM120B
Intelligence (Savage-Jansen 2018)	4.37	4	3	6.7	-0.97	3.1e-02	FBXO31 GPX1 RBM6 WNT3
Age at first live birth	4.37	2	2	4.4	0.00	1.0e+00	GPX1 RBM6
Ever highly irritable/argumentative for 2 days	4.35	1	1	2.2	0.00	1.0e+00	RBM6
Headache pain in last month	4.35	2	1	2.2	0.00	1.0e+00	TLR4 WNT3
Leg fat mass (right)	4.34	7	3	6.7	0.47	2.9e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Wheeze or whistling in the chest in last year	4.31	3	1	2.2	0.00	1.0e+00	GPX1 MVD RBM6
Lung FVC	4.29	7	3	6.7	-0.75	5.2e-02	DCC FBXO38 GPX1 MVD RBM6 TCF4 WNT3
Leg fat percentage (left)	4.21	5	3	6.7	0.56	3.2e-01	ANKK1 GPX1 MADD RBM6 TMEM120B
Age at First Birth	4.19	2	2	4.4	0.00	1.0e+00	GPX1 RBM6
Health satisfaction	4.19	2	0	0.0	0.00	1.0e+00	DRD2 GPX1
Arm fat mass (left)	4.13	7	4	8.9	0.38	4.0e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Arm fat mass (right)	4.11	7	4	8.9	0.39	3.8e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Medication: Paracetamol	4.11	2	2	4.4	0.00	1.0e+00	GPX1 WNT3
Medication: Paracetamol	4.11	2	1	2.2	0.00	1.0e+00	GPX1 WNT3
Relative age of first facial hair	4.10	2	1	2.2	0.00	1.0e+00	RBM6 WNT3
Impedance of arm (right)	4.10	6	4	8.9	-0.45	3.7e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM106B WNT3
Forced expiratory volume in 1-second (FEV1), predicted percentage	4.10	2	2	4.4	0.00	1.0e+00	FBXO38 WNT3
Ever unenthusiastic/disinterested for a whole week	4.09	2	0	0.0	0.00	1.0e+00	RBM6 WNT3
Impedance of arm (left)	4.04	5	4	8.9	-0.53	3.6e-01	AF131215.2 GPX1 RBM6 TMEM106B WNT3
Financial difficulties in last 2 years	4.03	2	0	0.0	0.00	1.0e+00	DRD2 TMEM106B
Arm fat percentage (left)	4.03	6	3	6.7	0.28	5.8e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 TMEM120B
Leg fat percentage (right)	3.98	4	3	6.7	0.54	4.6e-01	ANKK1 GPX1 MADD RBM6
Whole body fat mass	3.98	6	4	8.9	0.55	2.6e-01	ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Pain experienced in last month	3.96	4	1	2.2	-0.97	2.9e-02	GPX1 MVD PTK2 WNT3
Arm fat percentage (right)	3.94	7	3	6.7	0.33	4.7e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Depression (self-reported)	3.93	1	0	0.0	0.00	1.0e+00	TMEM106B
Forced vital capacity (FVC), Best measure	3.93	3	2	4.4	0.00	1.0e+00	FBXO38 GPX1 WNT3
Ever depressed for a whole week	3.91	1	0	0.0	0.00	1.0e+00	RBM6
Qualifications: None of the above	3.87	3	2	4.4	0.00	1.0e+00	GPX1 RBM6 TMEM120B
Number of self-reported non-cancer illnesses	3.87	1	0	0.0	0.00	1.0e+00	TMEM106B
BMI	3.86	7	3	6.7	0.52	2.3e-01	ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TLR4 TMEM120B
Body fat percentage	3.74	7	3	6.7	0.21	6.6e-01	ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B WNT3
Verbal and Numeric Reasoning (VNR)	3.66	3	2	4.4	0.00	1.0e+00	FBXO31 GPX1 RBM6
Forced vital capacity (FVC)	3.66	2	2	4.4	0.00	1.0e+00	GPX1 WNT3
Trunk fat percentage	3.64	8	3	6.7	0.02	9.6e-01	ANKK1 FBXO31 GPX1 MADD RBM6 SLC25A17 TMEM120B WNT3
Trunk fat mass	3.64	7	4	8.9	0.20	6.6e-01	ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B WNT3
Impedance of whole body	3.60	5	4	8.9	-0.42	4.8e-01	AF131215.2 GPX1 RBM6 SLC41A1 WNT3
Medication for pain relief, constipation, heartburn	3.54	3	1	2.2	0.00	1.0e+00	DLST GPX1 WNT3
Hand grip strength (left)	3.51	4	4	8.9	-0.66	3.4e-01	MADD SLC41A1 TCF4 WNT3
Comparative body size at age 10	3.51	3	2	4.4	0.00	1.0e+00	AF131215.2 MADD SLC41A1
Fluid intelligence score	3.50	4	1	2.2	-0.51	4.9e-01	GPX1 MADD RBM6 TMEM120B
Number of operations (self-reported)	3.50	2	0	0.0	0.00	1.0e+00	GPX1 RBM6
Average weekly beer plus cider intake	3.47	2	1	2.2	0.00	1.0e+00	AF131215.2 RBM6
Age when periods started (menarche)	3.45	3	2	4.4	0.00	1.0e+00	GPX1 MADD SLC41A1
Smoking Status	3.38	4	1	2.2	-0.78	2.2e-01	FBXO31 GPX1 TMEM120B WNT3
Waist circumference	3.33	5	3	6.7	0.55	3.4e-01	ANKK1 MADD RBM6 RP11-159N11.4 TMEM120B
Hearing difficulty/problems with background noise	3.30	2	0	0.0	0.00	1.0e+00	SLC41A1 WNT3
Current tobacco smoking	3.28	1	0	0.0	0.00	1.0e+00	SLC25A17
Number of full brothers	3.27	1	0	0.0	0.00	1.0e+00	WNT3
Emphysema/chronic bronchitis	3.16	1	0	0.0	0.00	1.0e+00	WNT3
Prostate Cancer	3.11	2	0	0.0	0.00	1.0e+00	GPX1 SLC41A1
Weight	3.04	7	3	6.7	0.41	3.7e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 SLC41A1 TMEM120B
Blood Red Count	3.03	3	2	4.4	0.00	1.0e+00	DRD2 MVD WNT3
Heel bone mineral density (BMD) T-score, automated (right)	3.00	1	1	2.2	0.00	1.0e+00	AF131215.2
Hand grip strength (right)	2.96	4	3	6.7	-0.61	3.9e-01	MADD SLC41A1 TCF4 WNT3
Heel bone mineral density (BMD) T-score, automated (left)	2.94	1	1	2.2	0.00	1.0e+00	AF131215.2
Hip circumference	2.88	5	3	6.7	0.34	5.7e-01	AF131215.2 GPX1 MADD RBM6 TMEM120B
Schizophrenia (2014)	2.85	3	0	0.0	0.00	1.0e+00	DRD2 SLC25A17 WNT3
Schizophrenia (2018)	2.83	2	0	0.0	0.00	1.0e+00	DCC SLC25A17
Fasting Glucose	2.80	1	1	2.2	0.00	1.0e+00	MADD
Systolic blood pressure, automated reading	2.80	4	3	6.7	0.59	4.1e-01	AF131215.2 FBXO38 GPX1 MADD
Sitting height	2.77	5	5	11.1	-0.37	5.4e-01	DCC FBXO31 MADD SLC41A1 WNT3
Handedness (chirality/laterality): Left-handed	2.76	1	1	2.2	0.00	1.0e+00	WNT3
Bipolar Disorder or Schizophrenia	2.74	2	1	2.2	0.00	1.0e+00	DCC SLC25A17
Impedance of leg (right)	2.72	5	4	8.9	-0.10	8.8e-01	AF131215.2 GPX1 MADD RBM6 SLC41A1
Hair/balding pattern: Pattern 2	2.72	1	1	2.2	0.00	1.0e+00	WNT3
Impedance of leg (left)	2.70	6	3	6.7	-0.13	8.1e-01	AF131215.2 GPX1 MADD RBM6 SLC41A1 WNT3
Leg pain on walking	2.68	1	0	0.0	0.00	1.0e+00	WNT3
High blood pressure	2.66	2	2	4.4	0.00	1.0e+00	AF131215.2 MADD
Chronic bronchitis/emphysema (mother)	2.66	1	0	0.0	0.00	1.0e+00	RBM6
Neck or shoulder pain in last month	2.65	2	0	0.0	0.00	1.0e+00	GPX1 PTK2
Number of incorrect matches in round	2.64	1	0	0.0	0.00	1.0e+00	SLC41A1
Chest pain or discomfort	2.63	1	0	0.0	0.00	1.0e+00	GPX1
Alcohol intake versus 10 years previously	2.60	1	0	0.0	0.00	1.0e+00	RBM6
Mouth/teeth dental problems: Mouth ulcers	2.60	1	1	2.2	0.00	1.0e+00	WNT3
Pack years adult smoking proportion	2.58	1	0	0.0	0.00	1.0e+00	GPX1
Back pain experienced in last month	2.58	1	0	0.0	0.00	1.0e+00	PTK2
Body Mass Index (BMI) (2010)	2.56	1	0	0.0	0.00	1.0e+00	MADD
Exposure to tobacco smoke outside home	2.52	1	0	0.0	0.00	1.0e+00	RBM6
Pack years of smoking	2.52	1	0	0.0	0.00	1.0e+00	GPX1
Father's age at death	2.50	1	0	0.0	0.00	1.0e+00	GPX1
Vascular/heart problems diagnosed by doctor	2.50	2	1	2.2	0.00	1.0e+00	AF131215.2 MADD
Time employed in main current job	2.49	1	1	2.2	0.00	1.0e+00	WNT3
Hypertension (Self-reported)	2.49	2	1	2.2	0.00	1.0e+00	AF131215.2 MADD
Ovarian Cancer	2.46	1	1	2.2	0.00	1.0e+00	WNT3
Average weekly champagne plus white wine intake	2.46	1	0	0.0	0.00	1.0e+00	WNT3
Irritable Bowel Disease (IBD)	2.42	2	1	2.2	0.00	1.0e+00	GPX1 RBM6
Mouth/teeth dental problems	2.42	1	0	0.0	0.00	1.0e+00	WNT3
Qualifications: O levels/GCSEs or equivalent	2.42	1	1	2.2	0.00	1.0e+00	GPX1
Systolic Blood Pressure	2.39	4	2	4.4	0.81	1.9e-01	FBXO38 GPX1 MADD PTK2
Comparative height size at age 10	2.36	5	4	8.9	-0.59	3.0e-01	DLST GPX1 SLC41A1 TCF4 WNT3
Arm predicted mass (left)	2.36	5	4	8.9	0.29	6.4e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Medication: Bendroflumethiazide	2.35	2	0	0.0	0.00	1.0e+00	AF131215.2 MADD
Ulcerative Colitis (UC)	2.34	2	1	2.2	0.00	1.0e+00	GPX1 RBM6
Arm fat-free mass (left)	2.33	5	3	6.7	0.32	6.0e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Diabetes diagnosed by doctor	2.31	1	0	0.0	0.00	1.0e+00	RBM6
Mouth/teeth dental problems: Dentures	2.30	2	0	0.0	0.00	1.0e+00	GPX1 RBM6
Average weekly red wine intake	2.30	1	0	0.0	0.00	1.0e+00	RBM6
Mean Putamen Volume	2.29	1	0	0.0	0.00	1.0e+00	WNT3
Asthma (self-reported)	2.28	2	0	0.0	0.00	1.0e+00	MVD RBM6
Arm predicted mass (right)	2.26	5	3	6.7	0.25	6.8e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Alzheimer’s Disease (including proxy)	2.24	1	0	0.0	0.00	1.0e+00	MADD
Cardiovascular Disease	2.24	2	0	0.0	0.00	1.0e+00	DRD2 RP11-159N11.4
Mean time to correctly identify matches	2.24	2	0	0.0	0.00	1.0e+00	FBXO31 SLC41A1
Diastolic blood pressure, automated reading	2.24	4	1	2.2	0.49	5.1e-01	AF131215.2 GPX1 MADD RBM6
Medication: Co-codamol	2.23	1	0	0.0	0.00	1.0e+00	RBM6
Arm fat-free mass (right)	2.22	5	3	6.7	0.27	6.6e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Relative age voice broke	2.20	1	1	2.2	0.00	1.0e+00	WNT3
Asthma	2.20	2	0	0.0	0.00	1.0e+00	MVD RBM6
Respiratory disease	2.19	2	0	0.0	0.00	1.0e+00	MVD RBM6
Waist Hip Ratio (WHR)	2.17	4	2	4.4	0.15	8.5e-01	GPX1 PTK2 RP11-159N11.4 WNT3
Type 2 Diabetes (T2D) (2018)	2.16	1	0	0.0	0.00	1.0e+00	RBM6
Leg predicted mass (left)	2.11	5	3	6.7	0.21	7.4e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Leg fat-free mass (left)	2.10	5	3	6.7	0.21	7.4e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Basal metabolic rate	2.10	5	3	6.7	0.27	6.6e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Leg fat-free mass (right)	2.09	4	3	6.7	0.18	8.2e-01	AF131215.2 RBM6 SLC41A1 TMEM120B
Exposure to tobacco smoke at home	2.07	1	0	0.0	0.00	1.0e+00	RBM6
Qualifications: CSEs or equivalent	2.06	1	0	0.0	0.00	1.0e+00	WNT3
Leg predicted mass (right)	2.06	4	3	6.7	0.18	8.2e-01	AF131215.2 RBM6 SLC41A1 TMEM120B
Ulcerative Colitis	2.03	1	1	2.2	0.00	1.0e+00	GPX1
Past tobacco smoking	2.03	1	0	0.0	0.00	1.0e+00	WNT3
Hypothyroidism/myxoedema (self-reported)	2.02	1	0	0.0	0.00	1.0e+00	AF131215.2
Medication: Seretide 50 evohaler	2.01	1	0	0.0	0.00	1.0e+00	RBM6
Diabetes (self-reported)	2.00	1	0	0.0	0.00	1.0e+00	RBM6
Reaction Time	1.98	1	0	0.0	0.00	1.0e+00	FBXO31
Number of live births	1.90	2	0	0.0	0.00	1.0e+00	RBM6 WNT3
Risk taking	1.89	1	0	0.0	0.00	1.0e+00	AF131215.2
Breast Cancer	1.85	1	1	2.2	0.00	1.0e+00	WNT3
Whole body water mass	1.85	5	3	6.7	0.21	7.3e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Whole body fat-free mass	1.82	5	3	6.7	0.21	7.4e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
High blood pressure (siblings)	1.80	1	0	0.0	0.00	1.0e+00	TMEM106B
Crohns Disease (2017)	1.77	1	1	2.2	0.00	1.0e+00	GPX1
Medication: Blood pressure	1.75	1	0	0.0	0.00	1.0e+00	AF131215.2
Illnesses of father: High blood pressure	1.68	1	0	0.0	0.00	1.0e+00	MADD
Hearing difficulty/problems: Yes	1.67	1	0	0.0	0.00	1.0e+00	PTK2
Standing height	1.67	5	4	8.9	-0.58	3.1e-01	GPX1 MADD SLC41A1 TMEM106B WNT3
Lupus	1.64	1	0	0.0	0.00	1.0e+00	AF131215.2
Chronotype (morning person)	1.61	1	0	0.0	0.00	1.0e+00	RP11-159N11.4
Blood Eosinophil Count	1.59	5	3	6.7	0.10	8.7e-01	FBXO38 GPX1 RBM6 SLC25A17 WNT3
Blood Platelet Count	1.59	5	3	6.7	0.48	4.1e-01	DLST MADD PTK2 TMEM120B WNT3
Supplements: Vitamin C	1.59	1	0	0.0	0.00	1.0e+00	WNT3
Trunk fat-free mass	1.58	3	2	4.4	0.00	1.0e+00	AF131215.2 RBM6 SLC41A1
Trunk predicted mass	1.58	3	2	4.4	0.00	1.0e+00	AF131215.2 RBM6 SLC41A1
Illnesses of father: Heart disease	1.57	1	0	0.0	0.00	1.0e+00	WNT3
Height	1.55	9	9	20.0	-0.29	4.5e-01	DCC GPX1 MADD MVD SLC41A1 TCF4 TMEM106B TMEM120B WNT3
Fractured/broken bones in last 5 years	1.55	1	0	0.0	0.00	1.0e+00	WNT3
Primary Biliary Cirrhosis	1.51	1	0	0.0	0.00	1.0e+00	WNT3
Birth weight	1.47	1	0	0.0	0.00	1.0e+00	SLC41A1
Heel T-Score	1.42	6	2	4.4	-0.26	6.2e-01	DLST MADD RBM6 SLC25A17 TMEM120B WNT3
Blood White Count	1.41	5	3	6.7	0.41	4.9e-01	FBXO38 GPX1 MADD RBM6 WNT3
Allergy or Eczema	1.26	1	1	2.2	0.00	1.0e+00	SLC25A17
Hair Pigment	0.46	5	2	4.4	0.61	2.7e-01	FBXO31 MVD SLC25A17 SLC41A1 WNT3
Tanning	0.45	1	0	0.0	0.00	1.0e+00	MVD

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Uterus	8	1.411	2.4
GTEx	Ovary	7	0.771	2.2
GTEx	Small Intestine Terminal Ileum	4	0.868	2.2
GTEx	Artery Coronary	10	0.845	2.1
GTEx	Brain Cortex	10	0.966	2.1
GTEx	Brain Hippocampus	4	0.763	2.1
GTEx	Brain Hypothalamus	5	0.847	2.1
GTEx	Brain Putamen basal ganglia	4	0.641	2.1
GTEx	Cells EBV-transformed lymphocytes	12	0.843	2.1
GTEx	Adipose Visceral Omentum	11	0.540	2.0
GTEx	Artery Aorta	12	0.403	2.0
GTEx	Brain Caudate basal ganglia	7	0.761	2.0
GTEx	Brain Frontal Cortex BA9	6	0.649	2.0
GTEx	Brain Nucleus accumbens basal ganglia	7	0.809	2.0
GTEx	Breast Mammary Tissue (Male)	7	0.587	2.0
GTEx	Breast Mammary Tissue (Female)	9	0.547	2.0
GTEx	Colon Sigmoid	10	0.684	2.0
GTEx	Esophagus Gastroesophageal Junction	10	0.692	2.0
GTEx	Esophagus Muscularis	17	0.526	2.0
GTEx	Heart Left Ventricle	9	0.588	2.0
GTEx	Liver	4	0.558	2.0
GTEx	Pituitary	6	0.538	2.0
GTEx	Prostate	7	0.838	2.0
GTEx	Skin Not Sun Exposed Suprapubic	12	0.488	2.0
GTEx	Spleen	9	0.638	2.0
GTEx	Stomach	9	0.619	2.0
GTEx	Vagina	6	0.945	2.0
The Cancer Genome Atlas	Esophageal Carcinoma	3	0.438	2.0
GTEx	Adrenal Gland	8	0.549	1.9
GTEx	Brain Cerebellar Hemisphere	10	0.672	1.9
GTEx	Brain Cerebellum	12	0.605	1.9
GTEx	Breast Mammary Tissue	9	0.456	1.9
GTEx	Colon Transverse	10	0.484	1.9
GTEx	Esophagus Mucosa	16	0.482	1.9
GTEx	Heart Atrial Appendage	8	0.507	1.9
GTEx	Lung	13	0.452	1.9
GTEx	Pancreas	9	0.551	1.9
GTEx	Skin Sun Exposed Lower leg	15	0.412	1.9
GTEx	Testis	11	0.349	1.9
GTEx	Adipose Subcutaneous	12	0.344	1.8
GTEx	Artery Tibial	8	0.213	1.8
GTEx	Cells Transformed fibroblasts	11	0.262	1.8
GTEx	Muscle Skeletal	10	0.346	1.8
GTEx	Nerve Tibial	12	0.278	1.8
GTEx	Thyroid	16	0.400	1.8
GTEx	Whole Blood	6	0.301	1.8
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.273	1.8
The Cancer Genome Atlas	Colon Adenocarcinoma	4	0.194	1.8
The Cancer Genome Atlas	Glioblastoma Multiforme	4	0.391	1.8
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	7	0.257	1.8
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	3	0.146	1.8
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	5	0.314	1.8
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	3	0.181	1.8
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	3	0.226	1.8
The Cancer Genome Atlas	Stomach Adenocarcinoma	5	0.297	1.8
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.394	1.8
METSIM	Adipose	4	0.087	1.7
NTR	Blood	8	0.333	1.7
ROSMAP	Brain Pre-frontal Cortex	5	0.114	1.7
CommonMind	Brain Pre-frontal Cortex	6	0.112	1.7
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.181	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	8	0.272	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	6	0.239	1.7
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.289	1.7
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.281	1.7
The Cancer Genome Atlas	Testicular Germ Cell Tumors	4	0.313	1.7
YFS	Blood	7	0.152	1.6
The Cancer Genome Atlas	Breast Invasive Carcinoma	5	0.113	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	6	0.146	1.6
The Cancer Genome Atlas	Brain Lower Grade Glioma	4	0.093	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	8	0.173	1.6
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.6
The Cancer Genome Atlas	Thyroid Carcinoma	6	0.116	1.6